Search research articles
Contact Us
Filters
Showing results (41-50 of 482) with videos related to
Page
of 49
Sort By:
European Journal of Haematology
|
August 1, 2024
Health-related quality of life in older hematological cancer survivors (70+) compared to older general population-A German cancer-register-based cross-sectional comparative study
Florian Schatz, Anja Mehnert-Theuerkauf, Uwe Platzbecker, et al.
Neoplasia (New York, N.Y.)
|
October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
Sebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancers
|
October 27, 2019
Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
Madlen Jentzsch, Sebastian Schwind, Enrica Bach, et al.
Acta Haematologica
|
May 26, 2023
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
Moshe Mittelman, Uwe Platzbecker, Sebastian Grosicki, et al.
Frontiers in Medicine
|
September 7, 2021
Production and Application of CAR T Cells: Current and Future Role of Europe
Vladan Vucinic, Andrea Quaiser, Philipp Lückemeier, et al.
Current Pharmaceutical Design
|
February 27, 2016
Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Anna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, et al.
European Journal of Haematology
|
March 22, 2017
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine
Markus Radsak, Uwe Platzbecker, Cornelia S Schmidt, et al.
Molecular Aspects of Medicine
|
July 5, 2020
Iron overload and its impact on outcome of patients with hematological diseases
Georg-Nikolaus Franke, Anne Sophie Kubasch, Michael Cross, et al.
Annals of Hematology
|
August 13, 2013
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
Judith Neukirchen, Uwe Platzbecker, Katja Sockel, et al.
Current Treatment Options in Oncology
|
February 1, 2020
Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
Sebastian Schwind, Madlen Jentzsch, Enrica Bach, et al.
Page
of 49
Search research articles
Search
Showing results (41-50 of 482) with videos related to
Sort By:
Page
of 49
European Journal of Haematology
|
August 1, 2024
Health-related quality of life in older hematological cancer survivors (70+) compared to older general population-A German cancer-register-based cross-sectional comparative study
Florian Schatz, Anja Mehnert-Theuerkauf, Uwe Platzbecker, et al.
Neoplasia (New York, N.Y.)
|
October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
Sebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancers
|
October 27, 2019
Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
Madlen Jentzsch, Sebastian Schwind, Enrica Bach, et al.
Acta Haematologica
|
May 26, 2023
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
Moshe Mittelman, Uwe Platzbecker, Sebastian Grosicki, et al.
Frontiers in Medicine
|
September 7, 2021
Production and Application of CAR T Cells: Current and Future Role of Europe
Vladan Vucinic, Andrea Quaiser, Philipp Lückemeier, et al.
Current Pharmaceutical Design
|
February 27, 2016
Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Anna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, et al.
European Journal of Haematology
|
March 22, 2017
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine
Markus Radsak, Uwe Platzbecker, Cornelia S Schmidt, et al.
Molecular Aspects of Medicine
|
July 5, 2020
Iron overload and its impact on outcome of patients with hematological diseases
Georg-Nikolaus Franke, Anne Sophie Kubasch, Michael Cross, et al.
Annals of Hematology
|
August 13, 2013
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
Judith Neukirchen, Uwe Platzbecker, Katja Sockel, et al.
Current Treatment Options in Oncology
|
February 1, 2020
Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
Sebastian Schwind, Madlen Jentzsch, Enrica Bach, et al.
Page
of 49